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Abstract
4-Amino-4-deoxychorismate lyase (PabC) catalyzes the formation of 4-aminobenzoate, and release of pyruvate, during
folate biosynthesis. This is an essential activity for the growth of Gram-negative bacteria, including important pathogens
such as Pseudomonas aeruginosa. A high-resolution (1.75 A ˚) crystal structure of PabC from P. aeruginosa has been
determined, and sequence-structure comparisons with orthologous structures are reported. Residues around the pyridoxal
59-phosphate cofactor are highly conserved adding support to aspects of a mechanism generic for enzymes carrying that
cofactor. However, we suggest that PabC can be classified into two groups depending upon whether an active site and
structurally conserved tyrosine is provided from the polypeptide that mainly forms an active site or from the partner subunit
in the dimeric assembly. We considered that the conserved tyrosine might indicate a direct role in catalysis: that of
providing a proton to reduce the olefin moiety of substrate as pyruvate is released. A threonine had previously been
suggested to fulfill such a role prior to our observation of the structurally conserved tyrosine. We have been unable to
elucidate an experimentally determined structure of PabC in complex with ligands to inform on mechanism and substrate
specificity. Therefore we constructed a computational model of the catalytic intermediate docked into the enzyme active
site. The model suggests that the conserved tyrosine helps to create a hydrophobic wall on one side of the active site that
provides important interactions to bind the catalytic intermediate. However, this residue does not appear to participate in
interactions with the C atom that undergoes an sp
2 to sp
3 conversion as pyruvate is produced. The model and our
comparisons rather support the hypothesis that an active site threonine hydroxyl contributes a proton used in the reduction
of the substrate methylene to pyruvate methyl in the final stage of the mechanism.
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Introduction
Aminodeoxychorismate lyase catalyzes the formation of para-
aminobenzoate(PABA)from4-amino-4-deoxychorismate(Figure1)
as part of the biosynthetic route to folate [1][2]. The enzyme,
encoded by the pabC gene, is labeled as PabC.
In Escherichia coli and many other bacteria, PABA is synthesized
in two steps starting from chorismate [3]. The first step produces
4-amino-4-deoxychorismate [4] by transferring ammonia, derived
from glutamine, to chorismate. This reaction is performed by
PABA synthase, a heterodimer of proteins encoded by the pabA
and pabB genes [5]. 4-amino-4-deoxychorismate is then converted
to PABA with the loss of pyruvic acid (Figure 1). The pyridoxyl 59-
phosphate (PLP) - dependent PabC catalyzes this second step
[2][3][6][7]. In the Gram-positive Bacillus subtilis a third chemical
step is required for PABA biosynthesis. Chorismate is first
converted to 2-amino-2-deoxyisochorismate before production of
4-amino-4-deoxychorismate, which is then converted to PABA
and pyruvate by PabC [8].
PABA is required for the biosynthesis of folic acid and by
extension also of essential metabolites such as thymidylate and
methionine. In addition, PABA is required for biosynthesis of
antibiotics such as candicidin [9] and certain Streptomycetes even
possess additional copies of pabC, located in antibiotic production
operons [10].
The inhibition of PabC would reduce PABA levels and so
deplete the supply of folic acid available to the microorganism.
Provided that the microbe cannot obtain sufficient PABA from the
cellular environment or by other means these cells would be
expected to cease growth and die. This is what is observed in pabC
knockouts in E. coli [7], Pseudomonas aeruginosa [11], Helicobacter pylori
[12] and Acinetobacter baylyi [13]. A few anti-microbial agents exert
their effect through inhibition of folate biosynthesis. Sulphon-
amides for example deplete bacterial intracelluar folate levels by
inhibiting PABA synthase and dihydropteroate synthetase [14].
Combining novel PabC inhibitors with sulphonamides or with
other anti-folates such as the dihydrofolate reductase inhibitor
trimethoprim, could produce a synergistic anti-microbial effect
and new inhibitors of PabC would allow such a hypothesis to be
tested.
X-ray crystal structures of PabC from E. coli [15], Thermus
thermophilus [16] and Legionella pneumophila [Protein Data Bank
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overall fold to branched-chain amino acid transferases and D-
amino acid transferases [15][17][18]. These aminotransferases
have been investigated to identify potential inhibitors for example
in support of research for treatments of neurodegenerative disease
[19][20][21][22]. Moreover, since PLP-dependent enzymes pro-
vide opportunities for the design of mechanism-based suicide
inhibitors [17] this enzyme family appears an attractive one from
the perspective of structure and mechanism-based drug discovery.
The absence of the enzyme in humans and its essentiality in
various microbes suggests that inhibition of PabC offers the
possibility of new therapies targeting a range of microbial
infections and structural studies provide useful data to assess the
potential of this protein for such early stage drug discovery [23].
We have a particular interest in pathogens for which current
treatments are unsatisfactory, for example Gram-negative bacteria
such as P. aeruginosa, that are highly adaptable to their environment
and which possess efficient and varied drug-resistance mecha-
nisms. P. aeruginosa is often the cause of life-threatening infections
in people with cystic fibrosis, burns victims and immuno-
compromised individuals [24][25]. We describe the construction
of an efficient bacterial recombinant expression system, enzyme
purification and crystallization protocols, and report the high-
resolution crystal structure of PabC from P. aeruginosa (PaPabC).
Comparisons with previously determined PabC structures are
presented, concentrating on active site cofactor interactions. Our
structure-based comparisons identified the potential for a tyrosine
to participate in catalysis and suggested that a re-evaluation of a
published mechanism is warranted.
Materials and Methods
Cloning, protein purification and analytical
ultracentrifugation
The P. aeruginosa pabC gene (locus tag: PA2964) was amplified
from genomic DNA (American Type Culture Collection 47085,
strain PAO1) by PCR using the following primers:
PaPabC forward primer
59-CAT ATG CTG GAC TGG GTC GAC-39 (NdeI restriction
site in bold)
PaPabC reverse primer:
59-GGA TCC TCA GAA ATC CAG GTC G-39 (BamHI
restriction site in bold)
The PCR product was blunt-end ligated into a TOPO cloning
vector (Invitrogen) then ligated into a modified pET15b expression
vector (Novagen) that produces a hexahistidine-tag linked via a
tobacco-etch virus (TEV) protease cleavage site. The resulting
plasmid was heat-shock transformed into E. coli BL-21 (DE-3)
GOLD cells (Novagen). Cultures were grown at 37uCi n2Lo f
Luria-Bertani medium supplemented with 100 mgm L
21 carben-
icillin. Gene expression was induced, when the OD600 reached
0.6, by addition of 1 mM IPTG and growth continued for a
further 16 hours at 18uC. Cells were harvested by centrifugation
(30006 g at 4uC for 30 minutes), resuspended in 50 mM Tris-
HCl, 200 mM NaCl, pH 7.5, and lysed by passage through a
French pressure cell. Cell lysate was clarified by ultracentrifugation
(400006g at 4(C for 30(minutes) and the supernatant was passed
through a 0.2 mm filter.
The lysate was loaded onto an immobilised metal ion affinity
chromatography column (5 mL HisTrap HP, GE Healthcare) with
the assistance of an FPLC system (A ¨kta Explorer, GE Healthcare).
The hexahistidine-tagged protein was eluted from the column by a
linear concentration gradient of imidazole and fractions were
analysed by SDS-PAGE. Selected fractions were pooled and
dialysed into 100 mM HEPES, 500 mM NaCl pH 7.5. Attempts
to cleave the hexa-histidine tag by addition of TEV protease had
produced large amounts of precipitate so it was decided to leave
the purification tag in place. The protein was further purified by
size exclusion gel chromatography (Superdex 200 26/60, GE
Healthcare). This column had previously been calibrated with
molecular weight standards, blue dextran (.2,000 kDa), thyro-
globulin (669 kDa), ferritin (440 kDa), aldolase (158 kDa),
conalbumin (75 kDa), ovalbumin (43 kDa), carbonic anhydrase
(29.5 kDa), ribonuclease A (13.7 kDa) and aprotinin (6.5 kDa);
(GE Healthcare; data not shown). Protein purity was assessed by
SDS-PAGE, matrix assisted laser desorption/ionisation – time of
flight mass spectrometry (MALDI-TOF MS) and electrospray
ionisation mass spectrometry.
The protein concentration was determined spectrophotometri-
cally using a theoretical extinction coefficient of 33,460 M
21 cm
21
(ProtParam, [26]).
Crystallization, X-ray data collection, structure solution
and refinement
PaPabC was crystallized at 20uC by the hanging drop vapour
diffusion method. The enzyme was concentrated to 33 mg mL
21
in 100 mM HEPES, 500 mM NaCl pH 7.5. Stock solutions of
PLP (100 mM in DMSO) and PABA (200 mM in deionized
water) were prepared and added to the PabC solution to give final
concentrations of 0.1 mM PLP and 10 mM PABA. The mixture
was left to incubate for 3 hrs then crystallization drops were
assembled by mixing 1 mL of the protein:ligand mixture with 1 mL
of reservoir containing 10% (w/v) PEG 400, 1.8 M ammonium
sulfate and 100 mM MES pH 6.5. Clumps of pale yellow,
Figure 1. PabC catalyzes the conversion of 4-amino-4-deoxychorismate to 4-aminobenzoate and pyruvate.
doi:10.1371/journal.pone.0024158.g001
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approximate dimensions 0.3 mm60.2 mm60.1 mm was used for
data collection. Addition of cryoprotectant (25% v/v glycerol) was
required to allow crystals to be mounted in a gaseous nitrogen
cryostream at 2173uC for diffraction experiments. Crystals were
initially characterized using a copper anode X-ray generator
(Rigaku 007) and an image plate detector (RAXIS IV
++). The
crystal was stored in liquid nitrogen for data collection at the
European Synchrotron Radiation Facility (ESRF, Grenoble,
France).
Diffraction data were collected on beamline ID29 at ESRF
using a Quantum4 CCD detector. It proved beneficial to use the
automated crystal annealing facility established on the station.
Data were indexed and integrated using MOSFLM [27], and
scaled with SCALA [28]. Crystallographic statistics are presented
in Table 1. The search model for molecular replacement was
prepared by generating a poly-alanine model of the E. coli PabC
structure (PDB code 1et0, [15]) from which all waters and non-
protein molecules had been removed. This model shares 35%
sequence identity with PaPabC. Molecular replacement calcula-
tions were performed using MOLREP [29].
Refinement was performed in REFMAC5 [30][31] and
the model was inspected and manipulated in COOT [32]. Strict
non-crystallographic symmetry restraints were employed in the
early stages of the refinement and then removed. The presence of
the PLP cofactor covalently bound to Lys140 was confirmed by
calculating an omit electron density map (Figure 2). The N-
terminal histidine tag was not visible in electron density maps. A
number of ligands (tetraethylene glycol, 1,2-ethanediol, di(hydrox-
ymethyl)ether, glycerol, chloride and sulfate ions) were assigned on
the basis of the difference density and chemical environment, and
refined satisfactorily. Both tetraethylene glycol and ethylene glycol
are likely decomposition products of PEG400 used in crystalliza-
tion, impurities or represent partially ordered molecules. MOL-
PROBITY [33] was used to assess model geometry, AREAIMOL
[31] and the Protein Interfaces, Surfaces and Assemblies, EMBL
server [http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html; [34]]
were used to calculate surface and interface areas. Figure 1 was
prepared with CHEMDRAW (Adept Scientific), Figure 5 with
ALINE [35] and the remainder using PyMOL [36] and
ILLUSTRATOR (Adobe Systems Inc.).
Amino acid sequence alignments and analysis
A search of the UniProt database with the Enzyme Commission
number for PabC (4-amino-4-deoxychorismate lyase; 4.1.3.38)
identified 368 entries. These were clustered such that sequences
Table 1. Crystallographic statistics.
Space group P 212121
Unit cell dimensions: a, b, c (A ˚) 40.8, 66.8, 202.7
Resolution range (A ˚) 30.00 - 1.75
Unique reflections 56255
Completeness (%) 98.9 (98.5)
a
,I/s(I). 10.7 (2.5)
Multiplicity 3.7 (3.3)
Rmerge
b 7.8 (45.1)
No. of reflections 53372
Rcryst
c, Rfree
d 16.7, 21.5
Protein residues 538
Ligands 26PLP, 3 Cl
2,2S O 4
22, 2 glycerol, 3 di(hydroxyethyl)ether, 5 tetraethyleneglycol, 3 1,2-ethanediol &
474 waters
r.m.s. deviations from ideal geometry
bond lengths (A ˚) 0.025
bond angles (u) 2.1
B values (A ˚2)
From Wilson Plot 18.4
Mean B values Chain A, main chain atoms: 15.1
Chain A, side chain atoms: 18.2
Chain B, main chain atoms: 18.5
Chain B, side chain atoms: 20.7
Waters: 30.8
PLP: Chain A 15.8 Chain B 21.5
Other ligands 36.3
Ramachandran favoured/allowed (%) 93.7/99.4 (3 outliers: Arg90, Chains A, B Leu89, Chain B)
aValues in parentheses refer to the highest resolution shell (1.8421.75 A ˚).
bRmerge=ghklgi|Ii(hkl)2,I(hkl).|/ghklgi Ii(hkl); where Ii(hkl) is the intensity of the ith measurement of reflection hkl and ,I(hkl). is the mean value of Ii(hkl) for all i
measurements.
cRcryst=ghkl||Fo|2|Fc||/g|Fo|, where Fo is the observed structure factor and Fc is the calculated structure factor.
dRfree is the same as Rcryst except calculated with a subset, 5%, of data that are excluded from refinement calculations.
doi:10.1371/journal.pone.0024158.t001
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representative sequence identified. This reduced the list to 197
entries. Sequences consisting of more than 400 amino acids were
removed and this further reduced the list to 181 entries. These
were aligned using MUSCLE [37] and then inspected following
pairwise alignment with PaPabC. A conservative group of 129
putative PabC sequences was then identified following the removal
of sequences that were fragmentary, labeled as other proteins or
which displayed a sequence identity of less than or equal to 20%.
Molecular modeling of the catalytic intermediate
A model of the substrate, 4-amino 4-deoxychorismate, was
prepared using PRODRG [38] and placed into the active site
using the molecular graphics program COOT [32] with the
position of the bound pyridoxyl 59 phosphate as a guide to allow
formation of the catalytic intermediate. The active site was
prepared for docking of this ligand using ICM pro (MolSoft L.L.C;
http://www.molsoft.com/index.html) with the centre of the
ligand-binding site defined by a cavity that contained the residues
within 5 A ˚ of the 4-amino 4-deoxychorismate. The top ten
docking poses, as scored by ICM Pro software gave similar
orientations in the active site and one was selected for discussion
and display.
Results and Discussion
Overall structure
Size exclusion gel filtration, carried out during protein
purification, indicated a single species of approximate mass
50 kDa that is commensurate with a homodimeric species. In
the crystal structure two polypeptide chains, labelled A and chain
B together constitute the asymmetric unit in PaPabC (Figure 3),
and the crystals have an estimated bulk solvent content of 45%.
The polypeptide chains form a dimer (Figure 3) and, as described
below, such oligomerization is required to create the enzyme
active site. The presence of a PaPabC dimer is consistent with
previous studies since all PabC structures solved to date are
dimeric or in the case of T. thermophilus PabC, a dimer-of-dimers is
observed [16].
The PaPabC subunits display a high degree of non-crystallo-
graphic symmetry. The rmsd following a least-squares fit of 270
Ca positions is 0.4 A ˚. It is therefore only necessary to detail one
subunit and one active site.
The PaPabC subunit is constructed from two domains (Figure 4).
The N-terminal domain (domain I) is smaller than the C-terminal
domain (domain II). Domain I comprises residues 1–107, which
Figure 2. The omit map for PLP and Lys140 from subunit A.
|(Fo)-(Fc)| difference density contoured at 3s (green chicken wire).
Selected hydrogen bonding associations between the protein, two
water molecules (red spheres) and PLP are depicted as dashed lines. A *
marks Tyr92 as contributed from subunit B. The side chain of Glu173
displays two rotamers with only one shown.
doi:10.1371/journal.pone.0024158.g002
Figure 3. The PaPabC dimer. Each subunit is depicted as a Ca trace
(yellow and purple) with the PLP shown as stick model in a similar
fashion to Figure 3. The N and C – terminal residue positions are
labelled.
doi:10.1371/journal.pone.0024158.g003
Figure 4. Ribbon diagram of the PaPabC monomer (b-sheet is
shown in purple, a-helix in yellow). Domain I is formed by a-helices
1–3 and the anti-parallel b-strands 1–4. Domain II is formed by a-helices
4–8 and b-strands 5–8.
doi:10.1371/journal.pone.0024158.g004
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sheet in order b1-b4-b3-b2. Domain II comprises residues 112–
271 that form five a-helices (a4–8), one short two-stranded parallel
b-sheet (b5–b6) and one short two-stranded anti-parallel b-sheet
(b7–b8). Residues 108–111 link the two domains. The PLP
cofactor is covalently bound to Lys140 that is in domain II. The
active site is formed in a cleft formed between the two domains
(Figure 3).
Sixty residues from each subunit, provided by both domains,
contribute to dimer formation. These residues participate in
around 30 hydrogen-bonding associations and eight salt bridge
interactions to stabilize the quaternary structure. Most of the
residues that contribute to the dimer interface are found in two
patches; residues Ala10 to Gly25 centred on a1 and residues
Arg127 to Ala152 centered on a5.
The approximate dimensions of the dimer, which constitutes the
asymmetric unit, are 80 A ˚640 A ˚640 A ˚ and this displays a solvent
accessible surface area of approximately 21,000 A ˚ 2. The contact
area between the two subunits occupies approximately 2,050 A ˚ 2,
about 15% of the surface of a subunit. These values are similar to
those observed for other PabC proteins, for example the interface
of the E. coli protein (PDB code 1et0) covers an area of 2,130 A ˚ 2.
The structures of PabC from three organisms (E. coli, L.
pneumophila and T. thermophilus) display a high degree of structural
conservation with PaPabC. Least-squares fitting of the Ca
positions of single subunits results in RMSD values of between
1.27 and 1.95 A ˚, with a coverage in the range of 81 to 92% of the
structures. The sequence identity shared with PaPabC, falls in the
range 26% to 35%.
The active site and mechanistic considerations
The active site of PaPabC is positioned between the two
domains of the monomer close to the dimer interface (Figure 3).
Here, the PLP cofactor is covalently linked to Lys140, bound and
oriented by interactions with key residues, a selection of which are
depicted in Figure 2. The PLP phosphate accepts hydrogen bonds
donated by a cluster of main chain amide groups from Val200,
Met201 and Ser237, and the side chain of Arg46. The side chain
of Arg46 is itself positioned by interactions with the side chain of
Glu28, which in turn accepts a hydrogen bond from His43 ND1.
Two well ordered water molecules mediate hydrogen bonding
networks linking the phosphate group to Asn178 OD1 and Arg202
N on one side, the main chain O and N groups of Thr29 on the
other. The cofactor ring is sandwiched between Val197 and the
main chain of a tripeptide segment comprising Val175-Phe176-
Ser177. A hydrogen bond between Asn236 ND2 and the carbonyl
of Phe176 in conjunction with hydrogen bonds formed between
the amide groups and the side chain of Glu161 helps to determine
the conformation of the tripeptide that forms a tight turn, between
b9 and b10, that covers part of the cofactor.
The PLP methyl group makes van der Waals interactions with
Gln147 CG and is positioned 3.2 A ˚ distant from the carbonyl
oxygen of Val175. The geometry of this latter contact is
compatible with the presence of a C-HNNNO hydrogen bond [39].
The side chain of Gln147 is held in place by a hydrogen bond with
Arg144 NE. The arginine side chain is itself positioned by
hydrogen bonds formed with the carbonyl groups of Leu139 and
His141. There are also three water molecules (data not shown),
which form a complex network of hydrogen bonds linking the side
chain of Arg144 to other sections of the enzyme. In addition the
positive dipole from a6, the closest residue on this helix is Gly199,
provides an attractive force to interact with the PLP phosphate.
The side chain of Glu173 displays a degree of conformational
freedom with two rotamers being observed. One rotamer places
the side chain to accept a hydrogen bond donated from PLP N1
(Figure 2). The alternative rotamer places the carboxylate at a
distance of 3.7 A ˚ from N1 (data not shown). Tyr92 from the
partner subunit forms a hydrogen bond to PLP O3. The cofactor
is also likely to posses an intra-molecular hydrogen bond involving
O3 and NZ of Lys140. The side chain of Phe27, Val197 and
aliphatic components of Arg46 and Arg144 surround the side
chain of Lys140.
No structures of PabC-ternary complexes have yet been
published to inform on aspects of substrate recognition and
enzyme activity. Given the importance of such complexes we
judged it important to get such data and attempted to determine
structures of PaPabC in complex with a number of compounds, for
example, the sample used for structure determination was
crystallized in the presence of 10 mM PABA. However, we have
been unable to identify electron density compatible with binding of
any such ligand in the substrate-binding pocket. We judged
therefore that the position of PLP and Lys140 NZ, together with
the conservation of amino acid sequence and structures give an
indication of where substrate binds and which residues are
important for substrate recognition and catalytic function.
Consideration of an amino acid sequence alignment and structural
overlay of PaPabC with three other structures in the PDB proved
particularly informative. To this we added molecular modelling
and docking of the covalent intermediate formed during catalysis.
The contributions of 24 residues, within about 5 A ˚ of PLP, to
binding the cofactor and organising the active site are described
above and summarized in Figure 5. Seven of these residues are
strictly conserved in PabC of P. aeruginosa, E. coli, L. pneumophila and
T. thermophilus (Phe27, Thr29, His43, Arg46, Gly199, Lys140 and
Arg202 in PaPabC). With one exception these residues contribute
to the active site using the chemical properties of their side chains.
The exception is Gly199 where any alteration on Ca would result
in a steric clash with the phosphate group of PLP. Another seven
residues contribute to the active site primarily through the
hydrogen bonding capacity of the main chain (Val175, Phe176,
Ser177, Leu139, His141, Val200 and Met201). Phe176 is not
conserved in any of the three other sequences but the remainder
are conserved in at least one other orthologue. Ser237 interacts
with the PLP phosphate using main chain and side chain groups.
This residue is only different in the E. coli sequence where an
alanine is observed and an additional water molecule binds nearby
helping to satisfy hydrogen-bonding capacity (data not shown). A
similar observation is made when considering PaPabC Asn236.
The residue is conserved in EcPabC and LpPabC but changed to
glycine in TtPabC where a water molecule is observed to replace
the side chain (data not shown). Asn178 is strictly conserved in
EcPabC and LpPabC but changed to serine in TtPabC. The side
chain here simply helps to form one side of the cofactor-binding
site. Val197 is conserved in EcPabC and conservatively substituted
as leucine in the other two sequences. The residue at this position
in the active site forms van der Waals interactions with the
cofactor. In PaPabC Arg144 NE donates hydrogen bonds to
Gln147 OE1 and the carbonyl of His141; interactions that help to
create one side of the cofactor-binding site and to fix the position
of Val197. These residues and the interactions they form appear to
be conserved in EcPabC but not in LpPabC or TtPabC. Sequence
and structure alignments (not shown) indicate that PaPabC Arg144
is replaced by tyrosine in both LpPabC and TtPabC and PaPabC
Gln147 replaced by an alanine in LpPabC and a tyrosine in
TtPabC. This is an intriguing observation to be discussed below.
There are three glutamates amongst the 24 residues discussed
above, Glu28, Glu161 and Glu173. Glu28 helps to position Arg46
to bind the cofactor phosphate. Both residues are strictly
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to threonine occurs in both EcPabc and TtPabC and the hydrogen
bonding interactions to support the role of an arginine binding the
cofactor are preserved. Glu161 helps to configure a tripeptide
segment to cover part of the cofactor and this feature is conserved
since a glutamate is present in the other structures or, as in
LpPabC an aspartate occupies this position. The carboxylate side
chain of Glu173 can interact directly with the cofactor by
accepting a hydrogen bond donated from N1. In a similar fashion
to what is observed for Glu161, such interactions occur in the
orthologues with the residue either strictly conserved, or as in
TtPabC, replaced by aspartate.
A catalytic mechanism, based on previous studies of PLP-
dependent enzymes, was proposed for PabC prior to any structural
data being available [10]. Following structure determination of
EcPabC, a model of substrate binding was prepared to inform an
assessment of the mechanism [15]. The contribution of PLP was
considered the same, that is, following covalent linkage the
enzyme-cofactor adduct undergoes a nucleophilic attack by the
substrate amino group to produce a reactive external aldimine.
This species then undergoes a-proton elimination, at C4, to the e-
amino group of a lysine to yield a reaction intermediate. In
EcPabC Lys159 forms the covalent link to the cofactor and likely
responsible for a-proton abstraction. Nakai et al., [15] further
Figure 5. Structure-based alignment of PaPabC and LpPabC. Residues encased in black are strictly conserved. Red stars indicate the tyrosine
residues at Position I (PaPabC Y92) and Position II (LpPabC Y144). Triangles mark residues that are discussed in the text. Red triangles identify Lys140
and residues that interact directly with the Lys140-PLP adduct; yellow triangles mark residues that contribute to the organization of the active siteo r
that participate in solvent mediated interactions between the protein and the cofactor.
doi:10.1371/journal.pone.0024158.g005
Figure 6. Structural conservation of tyrosine in the PabC active site. PLP is shown in the same manner as Figure 2. Left panel. A structural
overlay of PaPabC (green C atoms) and EcPabC (blue C atoms). Here, Tyr92 and Tyr109, which represent position I, are contributed from the partner
subunit. Centre panel. LpPabC. Right panel. TtPabC. Residue Thr27 displays two rotamers. In the LpPabC and TtPabC structures, Tyr144 and Tyr130
respectively represent position II and belong to the same subunit that forms the PLP-binding site.
doi:10.1371/journal.pone.0024158.g006
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olefin moiety of the substrate as pyruvate is released. To recover
the Schiff-base form of the enzyme, PABA is released and PLP
reacts with Lys159.
Three residues described as contributing to the mechanism of
action in EcPabC, Thr28, Lys97 and Lys159 [15], are strictly
conserved in PaPabC as Thr29, Lys80 and Lys140. They are also
conserved in LpPabC and TtPabC with the conservative change of
Lys80 to arginine in the thermophilic orthologue (Figure 5).
Lys140 of PaPabC is suitably placed to support a-proton
abstraction and although Thr29 may engage in the proposed
proton shuffling with both the olefin moiety of the substrate and
Lys80 we noted an alternative residue that might fulfil this role.
This residue may have been overlooked because Nakai et al., [15]
had access to only a single structure of PabC and alignments based
on sequences alone would not identify a tyrosine that is conserved
in three-dimensions.
In EcPabC and PaPabC tyrosine OH groups (Tyr109 and
Tyr92 respectively), from the partner subunit, donate a
hydrogen bond to PLP O3 (Figures 2, 6); an interaction that
influences the electronic structure of the cofactor [15]. The
sequence alignment of PabC orthologues suggests a degree of
variation in the identity of the amino acid that occupies the
position of this tyrosine (Figure 5). The structural overlays are
striking since they clearly identify a conserved tyrosine in
relation to the cofactor (Figure 6). In EcPabC and PaPabC,
Tyr109 and Tyr92 respectively, are contributed from the
partner subunit. We call this position I. However, in LpPabC
and TtPabC, Tyr144 and Tyr130 respectively, are contributed
f r o mt h es a m es u b u n i t ,o rp o s i t i o nI I .
We isolated 129 putative PabC sequences to investigate the
distribution of tyrosine at these two positions seeking to address the
hypothesis that if tyrosine is present at position I then it is likely
absent from position II and vice versa. This hypothesis holds true for
125 out of the 129 sequences (data not shown). Two sequences,
which share less than 30% sequence identity, have a tyrosine at
both positions. Analyses of the sequences suggests that PabC can
be classified into two groups depending on whether this active site
tyrosine is provided by the same subunit which primarily forms the
active site or from a partner subunit.
Furthermore the high degree of conservation of an active site
tyrosine in three-dimensional structures of PabC suggests a
functional role. One possibility is that this residue could act as a
proton donor for the methylene to methyl reduction that
completes the reaction. Such a reduction would have little
influence on the cleavage of the C-O bond of the substrate
since the driving force for that reaction would be production
of a conjugated aromatic six-carbon ring system. Our model
of the catalytic intermediate (Figure 7) was specifically created
to investigate the potential role of this active site tyrosine
and to re-evaluate the reduction process that completes the
reaction.
The model suggests that Tyr112 donates a hydrogen bond to
the C1 carboxylate whilst, with contributions from the partner
subunit, the main chain amide of Tyr92 and hydroxyl group of
Tyr22 donate hydrogen bonds to the other carboxylate of the
intermediate (Figure 7). Tyr92 contributes to the positioning and
electronic structure of the cofactor by virtue of the hydrogen bond
involving the hydroxyl group with the PLP carbonyl (Figure 2).
The bulk of the tyrosine side chain serves to create a hydrophobic
wall on one side of the active site. Although placed to interact with
the catalytic intermediate this residue does not appear to be
involved in donating a proton to convert methylene to methyl as
part of the catalytic cycle (Figure 7). Rather, Thr29, as first
postulated by Nakai et al., [15] appears to fulfil such a role with the
hydroxyl group placed about 3.5 A ˚ from the olefin (Figure 7).
Lys80 NZ is around 4.3 A ˚ distant from the sp
2 hybridized C and it
is possible that an alternative rotamer could bring this functional
group into play with respect to either providing a proton itself or in
activating the Thr29 hydroxyl for proton donation. We note that
Thr29 is strictly conserved in 123 out of the 129 PabC sequences
and conservatively substituted by serine in another five sequences.
The single sequence in which we could not identify conservation in
terms of a threonine or serine corresponding to Thr29 is the
putative PabC from Pantoea vagans. This is a poorly conserved
sequence sharing approximately 30% identity.
To further investigate the structure-activity relationship of
PabC, and to assess the potential of this enzyme as a target for
structure-based drug discovery will require the powerful combi-
nation of steady-state kinetic analysis with site-directed mutagen-
esis studies, and to carry out screening of chemical libraries. It will
be imperative to extend from our work and to elucidate a means
whereby structural data on enzyme-ligand complexes can be
obtained.
Figure 7. A stereoview of the catalytic intermediate docked into the active site of PaPabC. The protein components are colored as in
Figure 2. The C atoms of the modelled intermediate are black. Black dashed lines represent potential hydrogen bonding interactions, with a
separation of 3.5 A ˚ or less, and the red dashed line between Thr29 OG1 and the sp
2 hybridized C indicates the proximity of functional groups likely
involved in catalysis.
doi:10.1371/journal.pone.0024158.g007
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